Crescent Biopharma Inc (NASDAQ:CBIO) shares, rose in value on Wednesday, June 18, with the stock price up by 10.17% to the previous day’s close as strong demand from buyers drove the stock to $14.62.
Actively observing the price movement in the last trading, the stock closed the session at $13.27, falling within a range of $11.06 and $15.81. Referring to stock’s 52-week performance, its high was $63.00, and the low was $12.92. On the whole, CBIO has fluctuated by -43.73% over the past month.
With the market capitalization of Crescent Biopharma Inc currently standing at about $9.43 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2023-Oct-26.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CBIO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of CBIO currently trading nearly -24.96% and -33.79% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 28.01, while the 7-day volatility ratio is showing 11.38% which for the 30-day chart, stands at 5.29%. Furthermore, Crescent Biopharma Inc (CBIO)’s beta value is 1.60, and its average true range (ATR) is 2.51.
A comparison of Crescent Biopharma Inc (CBIO) with its peers suggests the former has fared considerably weaker in the market. CBIO showed an intraday change of 10.17% in last session, and over the past year, it shrunk by -44.41%%.
Data on historical trading for Crescent Biopharma Inc (NASDAQ:CBIO) indicates that the trading volumes over the past 3 months, they’ve averaged 18.91K. According to company’s latest data on outstanding shares, there are 0.65 million shares outstanding.
Nearly 13.04% of Crescent Biopharma Inc’s shares belong to company insiders and institutional investors own 43.01% of the company’s shares. The stock has fallen by -41.29% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CBIO stock heading into the next quarter.
